Contribution of procoagulant phospholipids, thrombomodulin activity and thrombin generation assays as prognostic factors in intensive care patients with septic and non-septic organ failure

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 2, 2013, Pages 387-396

  Van Dreden, Patrick ^a   Woodhams, Barry ^a   Rousseau, Aurélie ^a   Dreyfus, Jean François ^b   Vasse, Marc ^c,d  

^a Diagnostica Stago   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c FOCH HOSPITAL   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

calibrated automated thrombography; non septic organ failure; procoagulant phospholipids; sepsis; thrombomodulin activity; tissue factor activity

Indexed keywords

PHOSPHOLIPID; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN;

ADULT; ARTICLE; BLOOD CLOTTING TEST; CALIBRATED AUTOMATED THROMBOGRAPHY; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; INFLAMMATION; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; SEPSIS; THROMBOPLASTIN TIME;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PHOSPHOLIPIDS; PROGNOSIS; SEPSIS; THROMBIN; THROMBOMODULIN;

EID: 84875461896     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0262     Document Type: Article

References (50)

1. Chalupka AN, Talmor D. The economics of sepsis. Crit Care Clin 2012;28:57-76.
2. Levi M, van der Poll T, Schultz M. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunopathol 2012;34:167-79.
3. Kitchens CS. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematol Am Soc Hematol Educ Program 2009:240-6.
4. Saracco P, Vitale P, Scolfaro C, Pollio B, Pagliarino M, Timeus F. The coagulopathy in sepsis: significance and implications for treatment. Pediatr Rep 2011;3:e30.
5. Stief TW, Ijagha O, Weiste B, Herzum I, Renz H, Max M. Analysis of hemostasis alterations in sepsis. Blood Coagul Fibrinolysis 2007;18:179-86.
6. Egorina EM, Sovershaev MA, Hansen JB. The role of tissue factor in systemic inflammatory response syndrome. Blood Coagul Fibrinolysis 2011;22:451-6.
7. Gando S, Nanzaki S, Sasaki S, Kemmotsu O. A significant correlation between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1996;75:224-8.
8. Edgington TS, Mackman N, Fan ST, Ruf W. Cellular immune and cytokine pathways resulting in tissue factor expression and relevance to septic shock. Nouv Rev Fr Hematol 1992;34(Suppl):S15-27.
9. Srinivasan R, Ozhegov E, van den Berg YW, Aronow BJ, Franco RS, Palascak MB, et al. Splice variants of tissue factor promote monocyte-endothelial interactions by triggering the expression of cell adhesion molecules via integrin-mediated signaling. J Thromb Haemost 2011;9:2087-96.
10. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003;9:458-62.
11. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006;26:456-61.
12. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992;79: 2004-10.
13. Faust SN, Levin M, Harrison O, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of the endothelial protein C pathway in the coagulopathy of meningococcal sepsis. N Engl J Med 2001;345:408-16.
14. Strijbos MH, Rao C, Schmitz PI, Kraan J, Lamers CH, Sleijfer S, et al. Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. Thromb Haemost 2008;100:642-7.
15. Lind M, Boman K, Johansson L, Nilsson TK, Ohlin AK, Birgander LS, et al. Thrombomodulin as a marker for bleeding complications during warfarin treatment. Arch Intern Med 2009;169:1210-5.
16. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011;118:1952-61.
17. Mastronardi ML, Mostefai HA, Meziani F, Martãnez MC, Asfar P, Andriantsitohaina R. Circulating microparticles from septic shock patients exert differential tissue expression of enzymes related to inflammation and oxidative stress. Crit Care Med 2011;39:1739-48.
18. Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006;96:553-61.
19. Borgel D, Bornstain C, Reitsma PH, Lerolle N, Gandrille S, Dali-Ali F, et al. A comparative study of the protein C pathway in septic and nonseptic patients with organ failure. Am J Respir Crit Care Med 2007;176:878-85.
20. Collins PW, Macchiavello LI, Lewis SJ, Macartney NJ, Saayman AG, Luddington R, et al. Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. Br J Haematol 2006;135:220-7.
21. American College of Chest Physicians, Society of Critical Care Medecine. Consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
23. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicentric, prospective study. Crit Care Med 1998;26:1793-800.
24. Exner T, Joseph JE, Connor D, Low J, Ma DD. Increased procoagulant phospholipid activity in blood from patients with suspected acute coronary syndromes: a pilot study. Blood Coagul Fibrinolysis 2005;16:375-9.
25. Rousseau A, Favier R, Van Dreden P. Elevated circulating soluble thrombomodulin activity, tissue factor activity and circulating procoagulant phospholipids: new and useful markers for pre-eclampsia? Eur J Obstet Gynecol Reprod Biol 2009;146:46-9.
26. Van Dreden P, Rousseau A, Savoure A, Lenormand B, Fontaine S, Vasse M. Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction. Blood Coagul Fibrinolysis 2009;20:635-41.
27. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-30.
28. Levi M, Schultz M, van der Poll T. Coagulation biomarkers in critically ill patients. Crit Care Clin 2011;27:281-97.
29. Liaw PC, Esmon CT, Kahnamoui K, Schmidt S, Kahnamoui S, Ferrell G, et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004;104:3958-64.
30. Levi M, van der Poll T. Recombinant human activated protein C: current insights into its mechanism of action. Crit Care 2007;11(Suppl 5):S3.
31. Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost 2011;9:1795-803.
32. Schneider P, Van Dreden P, Rousseau A, Marie-Cardine A, Houivet E, Vannier JP, et al. Decreased activity of soluble thrombomodulin and plasma procoagulant phospholipids in childhood bone marrow transplantation with severe complications. Thromb Res 2011;128:261-7.
33. Ohlin AK, Larsson K, Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost 2005;3:976-82.
34. Grey ST, Hancock WW. A physiologic anti-inflammatory pathway based on thrombomodulin expression and generation of activated protein C by human mononuclear phagocytes. J Immunol 1996;156:2256-63.
35. Cicarelli DD, Vieira JE, Bensenor FE. C-reactive protein is not a useful indicator for infection in surgical intensive care units. Sao Paulo Med J 2009;127:350-4.
36. Aharon A, Katzenell S, Tamari T, Brenner B. Microparticles bearing tissue factor and tissue factor pathway inhibitor in gestational vascular complications. J Thromb Haemost 2009,6:1047-50.
37. Gando S, Kameue T, Morimoto Y, Matsuda N. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002;30: 1729-34.
38. Levi M. The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis. Crit Care Med 2002;30:1914-5.
39. Belaaouaj AA, Li A, Wun TC, Welgus HG, Shapiro SD. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem 2000;275:27123-8.
40. Shimura M, Wada H, Nakasaki T, Hiyoyama K, Mori Y, Nishikawa M, et al. Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1999;60: 94-8.
41. Joop K, Berckmans RJ, Nieuwland R, Berkhout J, Romijn FP, Hack CE, et al. Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001;85: 810-20.
42. Seo JW, Kim HK, Kim JE, Park S, Cho HI. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation. Thromb Res 2009;123:565-72.
43. Soriano AO, Jy W, Chirinos JA, Valdivia MA, Velasquez HS, Jimenez JJ, et al. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005;33:2540-6.
44. Mostefai HA, Meziani F, Mastronardi ML, Agouni A, Heymes C, Sargentini C, et al. Circulating microparticles from patients with septic shock exert protective role in vascular function. Am J Respir Crit Care Med 2008;178:1148-55.
45. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003;1:1655-62.
46. Petros S, Kliem P, Siegemund T, Siegemund R. Thrombin generation in severe sepsis. Thromb Res 2012;129: 797-800.
47. Mina A, Favaloro EJ, Koutts J. Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity. Blood Coagul Fibrinolysis 2012;23:203-7.
48. Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyák K, Ten C, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008;6:125-31.
49. Della Valle P, Pavani G, D'Angelo A. The protein C pathway and sepsis. Thromb Res 2012;129:296-300.
50. Bongers TN, Emonts M, de Maat MP, de Groot R, Lisman T, Hazelzet JA, et al. Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thromb Haemost 2010;103:1181-7.